Mason Carrico
Stock Analyst at Stephens & Co.
(1.76)
# 3,050
Out of 4,784 analysts
75
Total ratings
27.87%
Success rate
-7.91%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Reiterates: Overweight | $45 | $30.12 | +49.40% | 7 | Mar 26, 2025 | |
| OCX OncoCyte | Reiterates: Equal-Weight | $4 | $3.21 | +24.61% | 5 | Mar 26, 2025 | |
| GH Guardant Health | Reiterates: Overweight | $55 | $43.14 | +27.49% | 5 | Mar 26, 2025 | |
| AKYA Akoya Biosciences | Downgrades: Equal-Weight | $3.5 → $1.8 | $1.43 | +25.87% | 6 | Mar 25, 2025 | |
| CTKB Cytek Biosciences | Reiterates: Overweight | $6 | $4.00 | +50.00% | 2 | Mar 19, 2025 | |
| STAA STAAR Surgical Company | Reiterates: Equal-Weight | $17 | $17.79 | -4.44% | 2 | Mar 18, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $156 | $80.00 | +95.00% | 7 | Mar 11, 2025 | |
| ESTA Establishment Labs Holdings | Reiterates: Overweight | $52 | $40.43 | +28.62% | 2 | Mar 6, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $17.96 | +122.72% | 9 | Feb 27, 2025 | |
| PACB Pacific Biosciences of California | Reiterates: Overweight | $2.5 | $1.14 | +119.30% | 4 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 | $61.32 | +36.99% | 3 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $14 → $13 | $13.04 | -0.31% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $8.88 | +125.23% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $44.50 | +46.07% | 1 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $19.94 | +105.62% | 7 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $9.16 | +227.51% | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 | $143.94 | -13.16% | 4 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $19 | $9.62 | +97.51% | 1 | Jul 30, 2024 |
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $30.12
Upside: +49.40%
OncoCyte
Mar 26, 2025
Reiterates: Equal-Weight
Price Target: $4
Current: $3.21
Upside: +24.61%
Guardant Health
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $43.14
Upside: +27.49%
Akoya Biosciences
Mar 25, 2025
Downgrades: Equal-Weight
Price Target: $3.5 → $1.8
Current: $1.43
Upside: +25.87%
Cytek Biosciences
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $4.00
Upside: +50.00%
STAAR Surgical Company
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $17.79
Upside: -4.44%
Illumina
Mar 11, 2025
Reiterates: Overweight
Price Target: $156
Current: $80.00
Upside: +95.00%
Establishment Labs Holdings
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $40.43
Upside: +28.62%
CareDx
Feb 27, 2025
Reiterates: Overweight
Price Target: $40
Current: $17.96
Upside: +122.72%
Pacific Biosciences of California
Feb 18, 2025
Reiterates: Overweight
Price Target: $2.5
Current: $1.14
Upside: +119.30%
Feb 6, 2025
Reiterates: Overweight
Price Target: $84
Current: $61.32
Upside: +36.99%
Jan 30, 2025
Downgrades: Equal-Weight
Price Target: $14 → $13
Current: $13.04
Upside: -0.31%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $8.88
Upside: +125.23%
Jan 15, 2025
Reiterates: Overweight
Price Target: $65
Current: $44.50
Upside: +46.07%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $19.94
Upside: +105.62%
Oct 10, 2024
Reiterates: Overweight
Price Target: $30
Current: $9.16
Upside: +227.51%
Aug 9, 2024
Reiterates: Overweight
Price Target: $125
Current: $143.94
Upside: -13.16%
Jul 30, 2024
Reiterates: Overweight
Price Target: $19
Current: $9.62
Upside: +97.51%